Skip to main content
MedPathMedPath Home
Clinical Trials/EUCTR2012-004883-23-DK
EUCTR2012-004883-23-DK
Active, not recruiting
Phase 1

Individually tailored treatment in type 2 diabetes - Individually tailored treatment in type 2 diabetes

Henning Beck-Nielsen0 sitesDecember 20, 2012
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsType 2 diabetesMedDRA version: 16.1Level: LLTClassification code 10045242Term: Type II diabetes mellitusSystem Organ Class: 100000004861Therapeutic area: Diseases [C] - Hormonal diseases [C19]

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
Type 2 diabetes
Sponsor
Henning Beck-Nielsen
Status
Active, not recruiting
Last Updated
9 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
December 20, 2012
End Date
TBD
Last Updated
9 years ago
Study Type
Interventional clinical trial of medicinal product
Sex
All

Investigators

Sponsor
Henning Beck-Nielsen

Eligibility Criteria

Inclusion Criteria

  • •1\)Newly discovered T2D patients of both sex\`
  • •2\)Participation in the DD2 cohort
  • •3\)Signed informed consent
  • •Are the trial subjects under 18? no
  • •Number of subjects for this age range:
  • •F.1\.2 Adults (18\-64 years) yes
  • •F.1\.2\.1 Number of subjects for this age range 1696
  • •F.1\.3 Elderly (\>\=65 years) yes
  • •F.1\.3\.1 Number of subjects for this age range 550

Exclusion Criteria

  • •1\)Patients with age under 18
  • •2\)Type 1 diabetes
  • •3\)Life expectancy below 2 years
  • •4\)Psychiatric or mental disease
  • •5\)Ongoing abuse of alcohol or illicit drugs
  • •6\)Participation in any other clinical trial
  • •7\)Pregnancy at time of inclusion or planned future pregnancy (A negative pregnancy test is mandatory before inclusion. In women who are sterile, infertile or is postmenopausal (12 month without menstruation) this test is omitted.)

Outcomes

Primary Outcomes

Not specified

Similar Trials

Completed
Phase 1
Treating To Target in Type 2 diabetesType 2 diabetesNutritional, Metabolic, EndocrineNon-insulin-dependent diabetes mellitus
ISRCTN51125379ovo Nordisk Limited (UK)700
Completed
Phase 3
Improved treatment of type 2 diabetes mellitus by improving the splenic functions and gastro intestinal tract using naturally occurring bioactive compoundsSplenic and gastro intestinal disorder in Type 2 Diabetes Mellitusgastrointestinal disorderDiabetes mellitusMetabolic diseasesMetabolic and Endocrine - Diabetes
ACTRN12614000007639guyen Van Toan94
Completed
Not Applicable
Insulin combination therapy in type 2 diabetesDiabetes mellitus type 2 (DM type II)Nutritional, Metabolic, EndocrineDiabetes
ISRCTN29335793Stichting Julius Research (The Netherlands)200
Recruiting
Not Applicable
The role of Vitamin C in managing type 2 diabetes: Vitamin C, Thiazolidinediones and their combined effect onAdiponectiType 2 diabetesMetabolic and Endocrine - Diabetes
ACTRN12611000488909Princess Alexandra Hospital10
Recruiting
Not Applicable
Development of type 2 diabetes self-management support program in clinical settingType 2 diabetesPoor controlled diabetes
TCTR20120000018Preventive medicine and social department Faculty of medicine Chulalongkorn400